Icon Plc $ICLR Shares Sold by Boston Partners

Icon logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Boston Partners cut its ICON stake by 25.4% in the third quarter, selling 411,996 shares; it retained 1.21 million shares valued at about $205 million.
  • ICON’s latest quarterly results slightly beat expectations, with EPS of $2.66 versus $2.62 forecast and revenue of $2.02 billion versus $2.01 billion expected. Revenue was down 0.9% year over year.
  • Analysts’ consensus rating was “Moderate Buy,” with an average price target of $213.76. Company insiders sold 33,916 shares worth about $6.5 million over the prior 90 days.
  • Interested in Icon? Here are five stocks we like better.

Boston Partners decreased its stake in Icon Plc (NASDAQ:ICLR - Free Report) by 25.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,208,734 shares of the medical research company's stock after selling 411,996 shares during the quarter. Boston Partners owned approximately 1.58% of Icon worth $205,289,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Stephens Investment Management Group LLC lifted its position in shares of Icon by 7.1% during the 3rd quarter. Stephens Investment Management Group LLC now owns 771,246 shares of the medical research company's stock valued at $131,104,000 after buying an additional 50,985 shares in the last quarter. Muhlenkamp & Co. Inc. lifted its holdings in Icon by 1.1% during the third quarter. Muhlenkamp & Co. Inc. now owns 67,038 shares of the medical research company's stock valued at $11,396,000 after purchasing an additional 701 shares in the last quarter. Voya Investment Management LLC boosted its position in shares of Icon by 21.1% in the third quarter. Voya Investment Management LLC now owns 351,134 shares of the medical research company's stock worth $59,689,000 after purchasing an additional 61,216 shares during the period. HighTower Advisors LLC boosted its holdings in Icon by 26.9% in the 3rd quarter. HighTower Advisors LLC now owns 7,976 shares of the medical research company's stock worth $1,356,000 after buying an additional 1,692 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc grew its position in shares of Icon by 3.0% during the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 2,665 shares of the medical research company's stock worth $453,000 after purchasing an additional 77 shares in the last quarter. Institutional investors own 95.61% of the company's stock.

Icon Stock Performance

Shares of Icon stock opened at $190.36 on Friday. The business's 50 day moving average price is $181.49 and its 200 day moving average price is $147.63. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.32 and a current ratio of 1.32. The company has a market cap of $14.58 billion, a price-to-earnings ratio of 32.76, a PEG ratio of 10.81 and a beta of 1.19. Icon Plc has a one year low of $66.57 and a one year high of $219.04.

Icon (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.04. Icon had a net margin of 5.45% and a return on equity of 7.73%. The firm had revenue of $2.02 billion during the quarter, compared to analysts' expectations of $2.01 billion. During the same period last year, the business earned $3.31 earnings per share. Icon's revenue was down .9% compared to the same quarter last year. On average, research analysts predict that Icon Plc will post 9.71 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ICLR. Royal Bank Of Canada lifted their target price on Icon from $185.00 to $226.00 and gave the stock an "outperform" rating in a report on Thursday, October 29th. Zacks Research upgraded Icon from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 28th. Robert W. Baird increased their price target on shares of Icon from $210.00 to $249.00 and gave the company an "outperform" rating in a research report on Thursday, October 29th. Jefferies Financial Group reissued a "buy" rating and issued a $254.00 target price on shares of Icon in a research report on Thursday, October 29th. Finally, Deutsche Bank reiterated a "buy" rating and issued a $250.00 price objective on shares of Icon in a research note on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Icon currently has an average rating of "Moderate Buy" and a consensus target price of $213.76.

Check Out Our Latest Stock Report on Icon

Insider Transactions at Icon

In related news, Director Ciaran Murray sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $200.18, for a total value of $2,001,800.00. Following the completion of the transaction, the director directly owned 7,000 shares in the company, valued at approximately $1,401,260. This represents a 58.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronan Murphy sold 5,005 shares of the firm's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $175.00, for a total value of $875,875.00. Following the sale, the director directly owned 3,847 shares of the company's stock, valued at approximately $673,225. This trade represents a 56.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 33,916 shares of company stock valued at $6,514,252 in the last ninety days. 44.00% of the stock is currently owned by corporate insiders.

Icon Profile

(Free Report)

ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company's services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.

Read More

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR - Free Report).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Icon Right Now?

Before you consider Icon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Icon wasn't on the list.

While Icon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines